Modulating regulatory t cell activity via interleukin 35
AssigneeSt. Jude Children's Research Hospital
InventorsDario Vignali, Creg Workman, Lauren Collison, Kate Vignali
Life of this patent
Estimating the term…
Abstract
Methods for regulating T cell function in a subject, particularly regulatory T cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an Interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor. The invention further provides methods for enhancing the immunogenicity of a vaccine or overcoming a suppressed immune response to a vaccine in a subject, including administering to the subject a therapeutically effective amount of an IL35-specific binding agent and administering to the subject a vaccine. In one embodiment the vaccine is a cancer vaccine.
Claims16
A pharmaceutical composition comprising an excipient and an isolated human or humanized monoclonal antibody or antigen-binding fragment thereof capable of binding human Interleukin 35 (IL35) heterodimer, wherein the antibody is present in the composition in an amount effective to inhibit a regulatory T-cell function in a human subject to whom the composition is administered.
A monoclonal antibody that specifically binds IL35.
A method of inhibiting a regulatory T cell function in a subject, comprising administering to the subject a therapeutically effective amount of a specific binding agent, wherein said specific binding agent binds to IL35.
Dependencies are inferred from the claim text.